对比布地奈德联合异丙托溴铵与布地奈德联合沙丁胺醇雾化吸入对COPD急性加重期的疗效及不良反应

Effect and Adverse Reactions Comparison between Budesonide Combined with Ipratropium Bromide and Budesonide Combined with Salbutamol Nebulization Inhalation on Acute Exacerbation COPD

目的观察对比异丙托溴铵与沙丁胺醇分别联合布地奈德治疗慢性阻塞性肺病急性加重期的临床疗效与不良反应情况。方法选取2016年1月至2018年8月间我院收治的98例慢性阻塞性肺疾病急性加重期患者,并平均分成对照组与观察组,两组患者均行常规对症治疗,对照组另用布地奈德与沙丁胺醇进行雾化吸入治疗,而观察组另用布地奈德与异丙托溴氨进行雾化吸入治疗,对比两组治疗效果。结果观察组治疗有效率明显高于对照组,不良反应发生率明显低于对照组,组间差异均具有统计学意义(P<0.05)。结论布地奈德联合异丙托溴铵雾化吸入治疗慢性阻塞请肺疾病急性加重期的疗效更为效果显著,并且不良反应发生率更低,安全而可靠,可在临床进行推广应用。

Objective To observe and compare clinical effect and adverse reactions of ipratropium bromide and salbutamol combined with budesonide respectively in treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods Choose 98 cases acute exacerbation COPD patients admitted to our hospital from January 2016 to August 2018,divide them into control group and observation group in average.Both groups were treated with routine symptomatic treatment,control group was treated with budesonide and salbutamol aerosol inhalation,and observation group with budesonide and ipratropium bromide aerosol inhalation.Compare curative effect of two groups.Results Effective rate of observation group was significantly higher than control group,adverse reactions incidence was significantly lower than control group,difference between two groups was statistically significant,(P<0.05).Conclusion Budesonide combined with ipratropium bromide nebulization inhalation has better effect in treatment of acute exacerbation of chronic obstructive pulmonary disease,with lower adverse reactions incidence,and higher safety and reliability,which can be widely applied and promoted in clinical practice.